Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term Experience With Abatacept SC in Routine Clinical Practice

X
Trial Profile

Long-term Experience With Abatacept SC in Routine Clinical Practice

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASCORE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Aug 2022 Results assessing retention, efficacy, and safety of subcutaneous (SC) abatacept over 2 years in patients with moderate-to-severe rheumatoid arthritis, published in the Clinical Rheumatology.
    • 04 Jun 2022 Results of post-hoc analysis of two studies ((ACTION & ASCORE) assessing independent effect of ACPA or RF single seropositivity among patients with RA on achieving remission after treatment with abatacept for 2 years, and to compare outcomes among patients with single versus double serostatus, presented at the 23rd Annual Congress of the European League Against Rheumatism.
    • 04 Jun 2022 Results of post-hoc analysis of two studies (ACTION & ASCORE) assessing the independent effect of ACPA or RF single seropositivity on abatacept retention in patients with rheumatoid arthritis receiving abatacept, presented at the 23rd Annual Congress of the European League Against Rheumatism.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top